INDIA TO INTRODUCE FIRST INDIGENOUS H5N1 BIRD FLU VACCINE FOR CHICKENS

India is preparing to introduce its first indigenous vaccine against the H5N1 avian influenza virus affecting chickens, marking an important development in the country's efforts to strengthen poultry disease prevention and agricultural biosecurity.
Union Agriculture and Farmers Welfare Minister Shivraj Singh Chouhan is scheduled to dedicate the inactivated H5N1 vaccine, specifically developed against Clade 2.3.2.1a, to the nation on November 20 at the ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD) in Bhopal.
The vaccine has been developed domestically by researchers at ICAR-NIHSAD to address a significant gap in India's preparedness against highly pathogenic avian influenza.
Bird flu remains a serious threat to poultry production, with outbreaks capable of causing extremely high mortality among infected birds. Large-scale outbreaks can also result in the culling of poultry, restrictions on trade and substantial financial losses for farmers and businesses operating across the agricultural supply chain.
According to the Ministry of Agriculture and Farmers Welfare, India has recorded more than 500 combined outbreaks involving H5N1 and H5N8 subtypes since the disease was first detected in the country in 2006.
The Clade 2.3.2.1a strain has been responsible for most recent H5N1 outbreaks in chickens, making the development of a targeted vaccine particularly significant. The government noted that no specific commercial vaccine was available against this particular clade when the indigenous research programme was developed.
Beyond poultry farms, the disease also presents wider concerns involving animal health, public health and international agricultural trade. Its spread can affect the livelihoods of farmers, the availability of poultry products and the stability of related industries.
The development highlights the growing role of domestic scientific research in addressing agricultural challenges. It also reflects India's efforts to strengthen its capacity to develop vaccines and disease-control technologies within the country.
The upcoming dedication marks an important milestone, although the effectiveness of the broader programme will depend on its implementation, veterinary oversight and continued disease surveillance.



Comments